Company intelligence / Profile preview
Katmai Pharmaceuticals
Los Angeles, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Katmai Pharmaceuticals was founded in late 2019 by UCLA researchers and licensed intellectual property from UCLA for a novel small molecule inhibitor, ERAS‑801, targeting the EGFR/ERBB family in glioblastoma. The company’s lead asset has shown promise in preclinical models and entered early clinical development. No published Phase 2+ results yet.
- Therapeutic areas
- Oncology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
licensing IP from UCLA.
Beyond the preview
Go deeper on Katmai Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Katmai Pharmaceuticals.